Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer
February 28th 2015
Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.